New survey tracks Real-World use of entyvio for Crohn's disease
NCT ID NCT04002180
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This study is a survey of 335 people with moderate to severe Crohn's disease who are taking Entyvio (vedolizumab) as part of their regular care. The goal is to see how safe and effective the drug is over the long term in everyday medical practice. Researchers will track side effects and changes in disease activity. This is not a cure, but aims to help control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Takeda Selected Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI reads scans to forecast Crohn's complications
- Can stem cell vesicles heal Crohn's fistulas?
- Can a new drug calm the Gut's overactive immune response in Crohn's?
- Can a new drug keep Crohn's disease in check?
- Can a biologic drug tame Crohn's without steroids? a large Real-World study investigates
- Can a glass of pomegranate juice tame gut inflammation?